C-type lectin like 1Genealiases: CLECL1P · DCAL-1 · DCAL1
Q-omics provides the consensus-scored CLECL1 profile across patient tissues and cancer cell-line models. CLECL1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CLECL1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CLECL1 RNA expression shows 19,164 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where CLECL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLECL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLECL1 survival associations across molecular data types. CLECL1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLECL1 RNA expression–survival associations across cancer types. High CLECL1 expression shows favorable associations in HNSC, SKCM, LUAD, CESC, COAD and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CLECL1 RNA expression.
This table summarizes CLECL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CLECL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLECL1 shows lower tumor expression in COAD and BLCA and higher tumor expression in KIRC, KIRP, LUAD and BRCA. The KIRC box plot shows higher CLECL1 RNA expression in tumor versus normal tissue (log2 FC = +1.040, t-test p < 0.001).
This table shows molecular features associated with CLECL1 in patient tissues and cancer cell lines. In patient samples, CLECL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLECL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
